This study is designed to evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy following oral administration of AZD3470 as a monotherapy, and in combination with other anticancer agents in participants with haematologic malignancies.
Adequate adult (ECOG) or adolescent (Karnofsy or Lanksy) Performance Score assessments
Adequate organ and bone marrow function.
Part A (dose escalation): aged ≥ 18 years at the time of signing the informed consent.
Part B (optimization): aged ≥ 12 years of age. Adolescent participants must weigh ≥ 40 kg.
Any significant laboratory finding or any severe and uncontrolled medical condition.
Active CNS involvement by lymphoma, leptomeningeal disease, or spinal cord compression.
Serologic active HBV or HCV infection.
Known to have tested positive for HIV.
AstraZeneca
Lead sponsor